Research programme: cancer therapies - LipoNovaAlternative Names: LN020; LN030; LN040
Latest Information Update: 07 Oct 2009
At a glance
- Originator Liponova AG
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Leukaemia; Solid tumours
Most Recent Events
- 07 Oct 2009 Discontinued - Preclinical for Solid tumours in Germany (unspecified route)
- 07 Oct 2009 Discontinued - Preclinical for Leukaemia in Germany (unspecified route)
- 20 Apr 2007 Preclinical trials in Solid tumours in Germany (unspecified route)